Bactiguard Holding Ab · OMXSTO:BACTI_B
Bactiguard Holding Ab — Q2 2024 Earnings Presentation
15 slides from Bactiguard Holding Ab's earnings presentation, Jul 16, 2024
Slide 1: Interim report Q2 2024 presentation
Interim report Q2 2024 presentation Tuesday 16 July 2024 Christine Lind, CEO Patrick Bach, CFO
Slide 2: Q2 Summary: License revenues and EBITDA stabilizing
Q2 SUMMARY License revenues and EBITDA stabilizing
Slide 3: Q2 2024 key figures and highlights
Q2 2024 key figures and highlights License revenues and EBITDA stabilizing Key figures Q2 2024 (Q2 2023) Highlights from Q2 • Christine Lind appointed CEO in April Revenues 60.9 (51.2) MSEK • Thomas von Koch re-elected Chairperson at Annual General Meeting in May EBITDA 1.2 (-55.7) MSEK • ZNN Bactig
Slide 4: Nathaniel Bachrach appointed interim Head of R&D
Nathaniel Bachrach appointed interim Head of R&D Brings a wealth of experience from the MedTech industry and the scientific field • Product development executive with over 25 years of innovating, developing and launching advanced medical products for commercialization • PhD in mechanical engineering
Slide 5: Advanced infection prevention technology
Advanced infection prevention technology Reduces microbial adhesion and biofilm formation • Biocompatible, safe and proven – reduces the risk of medical device related infections • Ultra-thin noble metal coating technology; gold, silver and palladium • In contact with fluids, the noble metals create
Slide 6: Opportunities behind critical global healthcare trends
Opportunities behind critical global healthcare trends The issues The market opportunity (USD 80bn) • Antimicrobial resistance one of the top global public health threats facing humanity – associated with the Orthopedics 40 death of close to 5 million people globally in 2019 • 1 in 10 patients world
Slide 7: A knowledge and specialist organization
A knowledge and specialist organization Strategic focus areas to achieve profitable and sustainable growth R&D License Medical Wound Management partnerships Regulatory portfolio 7
Slide 8: BD collaboration in Q2
BD collaboration in Q2 Bactiguard’s longest and strongest partnership • Transition process for additional markets for coated Foleys continues according to plan • Knowledge sharing and training with BD sales – and marketing teams across Europe and the Middle East • All existing agreements in full for
Slide 9: Zimmer Biomet collaboration in Q2
Zimmer Biomet collaboration in Q2 Bactiguard goes East • Market activities across Europe continued • Introduction of ZNN Bactiguard at Annual Meeting of the Japanese Society for Fracture Repair • Bactiguard onsite with Zimmer Biomet APAC commercial teams, introducing our technology to the medical co
Slide 10: Wound Management by Bactiguard
Wound Management by Bactiguard Preventing infections by offering effective, biocompatible solutions to improve wound healing • Featured Hydrocyn aqua at the EWMA conference in London, receiving positive feedback from clinicians • Continued path of profitable growth during the second quarter At a gla
Slide 11: Total revenue Q2 2024
Total revenue Q2 2024 License revenues stabilizing • Total license revenue amounted to SEK 37.8 (24.8) million • Revenues from BD amounted to SEK 27.6 (18.5) million • Revenues from Zimmer Biomet Apr-Jun Jan-Jun Full year RTM amounted to SEK 10.2 (5.0) million MSEK 2024 2023 2024 2023 2023 2023/24 T
Slide 12: Total operating expenses and cash flow Q2 2024
Total operating expenses and cash flow Q2 2024 On track to deliver cost savings exceeding SEK 25 million on a yearly basis following the transformation Total operating expenses Total cash flow • Costs for raw materials and consumables • Cash flow from operating activities amounted amounted to SEK -1
Slide 13: Our priorities ahead – staying focused
Our priorities ahead – staying focused Vision: become the global standard of care for preventing medical device related infections • Current partnerships – BD, Zimmer Biomet and Well Lead • New partnerships in strategic therapeutic areas • Stable profitability within Wound Management • A knowledge a
Slide 14: Q&A to champion a healthier world by preventing infections
Q&A to champion a healthier world by preventing infections
Slide 15: Questions & Answers
Questions & Answers End of Q2 2024 presentation Christine Lind Patrick Bach CEO CFO